Drug Profile
Edaravone - Mitsubishi Tanabe Pharma
Alternative Names: 1-phenyl-3-methyl-5-pyrazolone; Edarabone; MCI-186; MT 1186; Norphenazone; Phenylmethylpyrazolone; RADICAVA; Radicava; RADICAVA ORS; RADICUT; Radicut; Radicut BagLatest Information Update: 10 Nov 2023
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Canada; Mitsubishi Tanabe Pharma Corporation
- Class Anti-ischaemics; Antidementias; Antihaemorrhagics; Antiparkinsonians; Hepatoprotectants; Neuroprotectants; Pyrazolones; Small molecules; Vascular disorder therapies
- Mechanism of Action Antioxidants; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Amyotrophic lateral sclerosis; Cerebral infarction
- Phase II Stroke
- No development reported Liver disorders
- Discontinued Myocardial ischaemia; Parkinson's disease; Reperfusion injury; Subarachnoid haemorrhage
Most Recent Events
- 07 Nov 2023 Edaravone has been added to the Provincial Drug Plans in Prince Edward Island, Newfoundland and Labrador
- 08 Aug 2023 Mitsubishi Tanabe Pharma completes a phase III trial for Amyotrophic lateral sclerosis in Canada, France, Germany, Italy, Japan, USA (PO) (NCT04577404)
- 31 Jul 2023 Mitsubishi Tanabe Pharma Corporation terminates a phase-III trial in Amyotrophic lateral sclerosis in US, Canada, Germany, Italy, Japan, South Korea and Switzerland based on the results from the pre-planned futility analysis (PO) (NCT05151471)